Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05667662
Registration number
NCT05667662
Ethics application status
Date submitted
1/12/2022
Date registered
28/12/2022
Date last updated
2/04/2024
Titles & IDs
Public title
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
Query!
Scientific title
Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With ABPA
Query!
Secondary ID [1]
0
0
601-0018
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
ABPA
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Itraconazole Powder
Treatment: Drugs - Placebo
Experimental: PUR1900 40 mg - 4 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
Experimental: PUR1900 20 mg - 2 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) and 2 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
Placebo Comparator: Placebo - 4 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
Treatment: Drugs: Itraconazole Powder
Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
Treatment: Drugs: Placebo
Capsules with 11.8 mg total powder (excipients only)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Treatment Emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
Review of TEAEs from time of consent to study completion.
Query!
Timepoint [1]
0
0
168 days
Query!
Primary outcome [2]
0
0
Safety spirometry assessments
Query!
Assessment method [2]
0
0
FEV1 (the volume of air (in liters) exhaled in the first second during forced exhalation after maximal inspiration), FVC (liters), and PEFR (L/min) measurements compared to baseline.
Query!
Timepoint [2]
0
0
168 days
Query!
Primary outcome [3]
0
0
Vital sign measurements
Query!
Assessment method [3]
0
0
Vital signs measurements collected before exposure, during and after treatment and compared to baseline. Vital sign measurements will include respiratory rate (bpm), blood pressure (mmHg), heart rate (bpm), oxygen saturation (by pulse oximetry), and oral or tympanic temperature (°C).
Query!
Timepoint [3]
0
0
168 days
Query!
Primary outcome [4]
0
0
Physical examinations
Query!
Assessment method [4]
0
0
At screening, a complete physical examination will be performed which includes measurement of height (cm), weight (kg) and evaluation of appearance; skin; head and neck; eyes, ears, nose, and throat; chest and lungs; heart; abdomen; neurological system; and extremities.
Query!
Timepoint [4]
0
0
168 Days
Query!
Primary outcome [5]
0
0
Clinical safety laboratory test results
Query!
Assessment method [5]
0
0
Hematology, serum chemistry, or urinalysis test results (normal, abnormal, clinical significance) compared to baseline.
Query!
Timepoint [5]
0
0
168 days
Query!
Primary outcome [6]
0
0
Cardiac safety monitoring
Query!
Assessment method [6]
0
0
Electrocardiogram (ECG) recordings collected before exposure, during and after treatment. Electrocardiogram measurements will include heart rate and PR, RR, QRS, and QT intervals, as well as the QTcF and compared to baseline.
Query!
Timepoint [6]
0
0
168 days
Query!
Secondary outcome [1]
0
0
Magnitude of effect of daily administration of PUR1900 - Spirometry
Query!
Assessment method [1]
0
0
Changes in measured Forced Expiratory Volume (FEV1) over time compared to baseline
Query!
Timepoint [1]
0
0
168 days
Query!
Secondary outcome [2]
0
0
Magnitude of effect of daily administration of PUR1900 - Patient Reported Outcomes (ACQ)
Query!
Assessment method [2]
0
0
Responses to the Asthma Control Questionnaire (ACQ) sored from 0-6 with 0 being totally controlled and 6 being extremely poorly controlled compared to baseline.
Query!
Timepoint [2]
0
0
168 days
Query!
Secondary outcome [3]
0
0
Magnitude of effect of daily administration of PUR1900 - Patient Reported Outcomes (AQLQ(s) 12+)
Query!
Assessment method [3]
0
0
Responses to the Asthma Quality of Life Questionnaire with scores ranging 1-7 and higher scores indicating better quality of life compared to baseline.
Query!
Timepoint [3]
0
0
168 days
Query!
Secondary outcome [4]
0
0
Frequency of asthma exacerbations versus baseline
Query!
Assessment method [4]
0
0
Occurrence of asthma exacerbations before, during, and after treatment with PUR1900
Query!
Timepoint [4]
0
0
168 days
Query!
Eligibility
Key inclusion criteria
- Is a male or female, =18 years old at the time of signing the informed consent.
- BMI of =18.0 and <40.0 kg/m2 at screening.
- Has a diagnosis of asthma, as per the Global Initiative for Asthma (GINA) 2018 update
- Has a confirmed diagnosis of ABPA, based on the modified International Society for
human and Animal Mycology (ISHAM) ABPA working group 2013 and 2021 criteria including
a history of or documentation at screening of serum IgE = 500 IU/mL and A.
fumigatus-specific IgE>0.35KUA/L, or above normal IgE antibody to A. fumigatus, or a
positive immediate skin test and at least 2 of the 3 following supportive criteria:
eosinophil count >500 cells/µL; A. fumigatus-specific IgG >27 mgA/L or presence of
precipitating (or above normal immunoglobulin G [IgG]) antibody to A. fumigatus;
consistent radiographic opacities or bronchiectasis on chest CT.
- Is currently considered to be in one of the following stages of ABPA: Stage 2
(Response), Stage 4 (Remission), Stage 5a (Treatment-dependent ABPA), or Stage 5b
(Glucocorticoid-dependent asthma).
- At least 1 exacerbation requiring a systemic glucocorticosteroid(s) in the 12 months
prior to Screening. For patients on a biologic agent, at least one exacerbation
requiring a systemic glucocorticosteroid(s) must have occurred at least 3 months after
the initiation of the biologic agent.
- Has a serum IgE =500 IU/mL at screening.
- Has a documented stable asthma medication regimen during the 28 days prior to the
first dose of study drug ; applicable asthma medications can include but are not
limited to the following: inhaled short-acting beta agonist (SABA), inhaled
long-acting beta agonist (LABA), and leukotriene receptor antagonist (LTRA) use and
inhaled and/or oral glucocorticosteroids. SABA use during this period should be mostly
within a stable range (e.g., 2 puffs 2 to 4 times a day) and should not exceed 8 puffs
a day on 2 out of 3 consecutive days.
- Can perform a valid, reproducible spirometry test with demonstration of a
prebronchodilator FEV1 =50% of predicted normal for age, sex, race, and height at a
screening visit.
- Can demonstrate the correct inhalation technique and achieve a minimum inspiratory
flow rate of 45 L/min for the use of the delivery device at screening and before
dosing on Day 1.
- Is willing and able to comply with all study procedures and assessments, including
scheduled visits, drug dosing plan, study procedures, laboratory tests, and study
restrictions.
- Subjects who are sexually active, male subjects able to father a child, and female
subjects of childbearing potential must agree to follow contraception requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Currently requiring medications that are sensitive substrates for CYP3A4-mediated
metabolism or medications that are contraindicated with oral itraconazole.
- Has evidence of ventricular dysfunction, such as congestive cardiac failure (New York
Heart Association functional class III or IV), or a history of congestive cardiac
failure. N-terminal pro B-type natriuretic peptide (NT pro BNP) will be checked at
screening only. A subject with a confirmed value of >400 pg/mL will not be eligible to
participate.
- Has used any systemic azole antifungal agent in the 6 weeks before first dose of study
drug.
- Has discontinued previously administered biologic agent(s) in the 3 months prior to
screening.
- Has a history of life-threatening asthma within the last 24 months, defined as an
asthma episode that required intubation and/or was associated with hypercapnia,
respiratory arrest, and/or hypoxic seizures.
- Has a current diagnosis of any chronic airway disease other than asthma, ABPA, or
bronchiectasis believed to be related to ABPA, such as chronic obstructive pulmonary
disease, pulmonary fibrosis, cystic fibrosis, or Churg-Strauss syndrome. A subject
whose predominating clinical disease burden is related to bronchiectasis (e.g., a
subject with 2 or more infective exacerbations of bronchiectasis in the past 12 months
or a subject with chronic colonization with Pseudomonas aeruginosa) will be excluded.
Refer to Appendix 4 for definition of bronchiectasis exacerbations.
- Had an occurrence of clinically significant bacterial, viral, or fungal infection that
required systemic (oral or intravenous) antibiotics, antivirals, or antifungals within
the 28 days before screening. Topical treatments, other than antifungals, are allowed.
- Had an occurrence of asthma or ABPA exacerbations within the 28 days before screening.
- Has the presence of hoarseness or oropharyngeal candidiasis at screening.
- Had a major trauma or surgery within the last 28-days before screening.
- Has a history of any clinically significant cardiovascular, renal, hepatic, or
gastrointestinal disease or neurological or psychiatric disorder endocrine,
immunological, or autoimmune disease or other medical condition that would affect the
subject's safety or confound the assessment of study endpoints as judged by the
Investigator.
- Has a history of any clinically significant drug or alcohol abuse in the past 6 months
before screening, as judged by the Investigator.
- Has current inhaled tobacco/nicotine or inhaled marijuana use or history of smoking or
vaping including tobacco or marijuana within the last 6 months before screening.
- Has a history of any clinically significant drug or alcohol abuse in the past 6 months
before screening, as judged by the Investigator.
- Has current tobacco or inhaled marijuana use or history of smoking or vaping including
tobacco or marijuana within the last 6 months before screening.
- Has a history of allergic or hypersensitivity reaction or serious adverse reaction
after dosing of itraconazole or other antifungal azoles.
- Has a history of serious adverse reaction or known serious hypersensitivity to any of
the formulation excipients.
- Has a positive urine test result for drugs of abuse or cotinine at screening (unless,
in the opinion of the Investigator, this can be explained by the subject's current
medications). Note that results that are positive for a drug of abuse or cotinine may
be acceptable for drugs that have been obtained by legal means or non-inhaled
tobacco/nicotine product use.
- At screening, has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
>2x upper limit of normal (ULN), white blood cell (WBC) count > 20,000 X 109/L,
absolute neutrophil count <1000 cells/L, platelet counts <100,000 to or >500,000 X
109/L, or hemoglobin <10 g/dL
- Is a female of childbearing potential who is pregnant or lactating or who plans to
become pregnant during the study. All female subjects must have a negative pregnancy
test at screening and pre dose on Day 1. A woman is of childbearing potential unless
she is either permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral
oophorectomy, bilateral tubal occlusion/ligation, endometrial ablation) or
postmenopausal (had no menses for 12 months without an alternative medical cause).
- Has a 12-lead ECG demonstrating a mean QT interval corrected by the Fridericia formula
(QTcF) >450 msec for a male subject or >470 msec for a female subject at screening. A
repeat triplicate ECG is allowed if a mean QTcF >450 msec for males and >470 msec for
females is recorded at Visit 1.
- Has a planned or elective surgery, hospitalizations, or participation in other
interventional studies any time during the study that may interfere with study
logistics or safety.
- Has donated or had a loss of greater than 400 mL of blood within the 3 months before
screening.
- Has other social, psychiatric, surgical, or medical conditions or screening laboratory
abnormalities that may increase the risk associated with study participation or may
interfere with the interpretation of study results and, in the judgement of the
Investigator, would make the subject inappropriate for entry into the study.
- Received any investigational medical product in a clinical research study within the
previous 3 months before first dose of study drug.
- Is a study site employee, an immediate family member of a study site employee, or a
Sponsor employee.
- Has previously received PUR1900.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/02/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
8
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Query!
Recruitment hospital [1]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [2]
0
0
Mater Hospital Brisbane, Respiratory Research Group - South Brisbane
Query!
Recruitment hospital [3]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
NSW 2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
QLD 4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Cedex 9
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Strasbourg Cedex
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Marseille
Query!
Country [10]
0
0
United Kingdom
Query!
State/province [10]
0
0
West Midlands
Query!
Country [11]
0
0
United Kingdom
Query!
State/province [11]
0
0
Glasgow
Query!
Country [12]
0
0
United Kingdom
Query!
State/province [12]
0
0
London
Query!
Country [13]
0
0
United Kingdom
Query!
State/province [13]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pulmatrix Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal
therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients
with asthma. The main questions it aims to answer are:
1. Is PUR1900 safe and well tolerated in adults with asthma and ABPA?
2. Is there an effect of daily administration of PUR1900 on potential outcome measures in
adults with asthma and ABPA?
3. Is there fungal resistance to A. fumigatus?
This study includes a 28-day screening period, a 112-day (16-week) treatment period, and a
56-day (8 week) observation period.
Participants will take either 40mg of PUR1900, 20 mg of PUR1900 or Placebo for 112 days and
complete an eDairy, answer questions about their asthma and complete peak respiratory flow
measurements at home. They will come to the clinic approximate once a month during the
treatment period and complete study assessments. At the end of the observation period
participants will complete one more clinic visit. Participants who complete this study may be
given the opportunity to continue on study drug in an open label extension study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05667662
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Chris Cabell, MD
Query!
Address
0
0
Pulmatrix Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05667662
Download to PDF